The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia - A pilot study involving serial sampling

Current Medical Research and Opinion

Volumn 16, Issue 4, 2000, Pages 269-275

  Goudevenos, J A ^a   Bairaktari, E T ^a   Chatzidimou, K G ^a   Milionis, H J ^b   Mikhailidis, D P ^b   Elisaf, M S ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Atorvastatin; Fibrinogen; Lipoprotein(a); Primary hypercholesterolaemia; Primary mixed hyperlipidaemia

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLASMINOGEN; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; TREATMENT OUTCOME;

EID: 0035100954     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079901750120204     Document Type: Article

References (34)

1. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
2. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia
3. Lp(a) lipoprotein in cardiovascular disease
4. Atherothrombogenicity of lipoprotein(a): The debate
5. Lowering fibrinogen levels: Clinical update
6. Measuring plasma fibrinogen to predict stroke and myocardial infarction
7. Effect of atorvastatin on plasma fibrinogen
8. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia
9. Statins and fibrinogen
10. Effect of atorvastatin versus simvastatin on lipid profile and plasma fibrinogen in patients with hypercholesterolaemia. A pilot, randomised, double-blind, dose-titrating study
11. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction
12. Atorvastatin compared to simvastatin-based therapies in the management of severe familial hyperlipidemias
13. Summary of the second report of the National Cholesterol Educational Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
14. Assessing dietary adherence in the Multiple Risk Factor Intervention Trial (MRFIT)
15. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
16. Lp(a) for quantitation of human lipoprotein (a) by enzyme linked immunoassay
17. The acute rise in plasma fibrinogen with exercise is influenced by the G-453-A polymorphism of the B-fibrinogen gene
18. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels
19. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia
20. Long-term variability of serum lipoprotein (a) concentrations in healthy fertile women
21. International Federation of Clinical Chemistry standardization project for the measurement of lipoprotein (a). Phase I. Evaluation of the analytical performance of lipoprotein (a) assay systems and commercial calibrators
22. Standardization and clinical management of lipoprotein (a) measurements
23. The effects of long term storage on serum Lp(a) levels
24. Atorvastatin: An effective agent in familial hypercholesterolemia
25. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
26. More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolemia
27. Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia
28. No difference in plasma fibrinogen levels between CAPD patients taking atorvastatin and simvastatin
29. Effect of atorvastatin on hemorheologichemostatic parameters and serum fibrinogen levels in hyperlipidemic patients
30. The effect of short term lipid lowering with atorvastatin on carotid artery intima media thickness in patients with peripheral vascular disease: A pilot study
31. More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolaemia
32. Fibrinogen as a cardiovascular risk factor
33. Treatment of dyslipidaemias in patients with established vascular disease: A review of the fibrates
34. Platelets and lipid lowering interventions